FDA Panel to Review First Thyroid Eye Disease Drug

]]>(MedPage Today) -- Whether teprotumumab's benefits in thyroid eye disease outweigh risks for muscle spasm and worsened bowel inflammation will be voted upon at Friday's meeting of the FDA's Dermatologic and Ophthalmic Drugs Advisory Committee...